Over the past decade, the development of ultrasensitive immunoassays has enabled the use of NfL as a clinically actionable biomarker—particularly in multiple sclerosis (MS), where there is a paramount need to detect subclinical disease activity and measure treatment efficacy. The gene discussed is NEFL; the disease is myeloid sarcoma.